A Phase 2 interventional study of Aitua Combination Antibody and Albumin-Bound Paclitaxel /nab-Paclitaxel in High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers and Primary Peritoneal Cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Fallopian Tube Neoplasms with a site in China — 33 open to participants now, 40 under way, 17 of them phase 3. Fallopian Tube Neoplasms · China.
Among the 59 studies in Fallopian Tube Neoplasms with a site in China, this one is the 41st largest by planned enrollment, is one of 12 that started in 2026, is one of 20 in phase 2, reaches primary completion later than 15 of the 39 other live ones, and was the 47th registered.
835 studies on the registry are indexed under Fallopian Tube Neoplasms; 128 are open to participants now.
Browse Fallopian Tube Neoplasms studies →33 of the 59 studies in Fallopian Tube Neoplasms with a site in China are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in China, United States, Israel and 2 more countries
Ages 18+ · Women only
AstraZeneca · Sites in China, United States, Australia and 10 more countries
Ages 18+ · Women only
AstraZeneca · Sites in China, United States, Argentina and 26 more countries
Ages 18+ · Women only
Shanghai Gynecologic Oncology Group · Sites in China
Ages 18–80 · Women only
CSPC Megalith Biopharmaceutical Co.,Ltd. · Sites in China
Ages 18+ · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 104 Fallopian Tube Neoplasms studies recruiting now, 85 (82%) set no upper age limit and 10 (10%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 25 · Phase 3 28
First in 2009; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 82 is above the median of 50 across 684 interventional studies indexed under Fallopian Tube Neoplasms.
Median enrollment 220 across the 59 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 59 have an industry lead sponsor. The 10 most frequent:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences is the lead sponsor of 396 studies on the registry; 281 are open to participants now.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences has 1 study filed under Fallopian Tube Neoplasms — fewer than ten, so there is no comparison to draw.
12 of the studies in Fallopian Tube Neoplasms with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT02859038Phase 3Shanghai Gynecologic Oncology GroupStudy of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients with Advanced Ovarian Cancer (SUNNY) | 2027-06 |
| NCT06994195Phase 3Sichuan Baili Pharmaceutical Co., Ltd.A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) | 2027-06 |
| NCT07604766Phase 3GenmabAn Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China | 2027-09 |
| NCT07480954Beijing BiotechDual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) | 2027-02-17 |
Add all 12 to your calendar (.ics) → With an account.
Among the 59 studies in Fallopian Tube Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, randomized, controlled Phase II clinical study designed to evaluate the efficacy and safety of adding Aitua Combination Antibody (a PD-1/CTLA-4 bispecific antibody) to standard neoadjuvant chemotherapy for patients with advanced high-grade serous ovarian cancer.
The study focuses on patients who are newly diagnosed with Stage IIIC-IV ovarian, fallopian tube, or primary peritoneal cancer and are assessed as unable to achieve satisfactory tumor debulking (R0 resection) initially.
Participants will be randomized in a 1:1 ratio into two groups:
Experimental Group: Receives Nab-paclitaxel and Carboplatin combined with Aitua Combination Antibody.
Control Group: Receives Nab-paclitaxel and Carboplatin alone.
Both groups will receive 3 cycles of neoadjuvant treatment followed by Interval Debulking Surgery (IDS). The primary goal is to compare the R0 resection rate (complete removal of macroscopic tumor) between the two groups during surgery. Secondary goals include assessing pathological complete response (pCR), objective response rate, progression-free survival, and safety. The study also aims to explore how this combination therapy affects the tumor immune microenvironment.
Background and Rationale: Ovarian cancer has the highest mortality rate among gynecological malignancies, with High-Grade Serous Carcinoma (HGSC) being the most common subtype. HGSC is characterized by a highly immunosuppressive Tumor Immune Microenvironment (TiME), often referred to as an "immune desert," which limits the efficacy of single-agent immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway.
Investigational Agent: Aitua Combination Antibody (QL1706) is a novel bifunctional antibody targeting both PD-1 and CTLA-4. Dual blockade of these pathways may synergistically activate anti-tumor immune responses: CTLA-4 inhibition promotes early T-cell activation in lymph nodes, while PD-1 inhibition reverses T-cell exhaustion within the tumor microenvironment. Previous studies in cervical cancer have shown that this bispecific antibody may offer improved efficacy with a manageable toxicity profile compared to combining two separate antibodies.
Chemotherapy Synergy: Albumin-bound paclitaxel (Nab-paclitaxel), a standard component of ovarian cancer treatment, avoids the need for corticosteroid pretreatment and has been shown to potentially enhance immune cell infiltration and regulate macrophage polarization. This study hypothesizes that combining Nab-paclitaxel/Carboplatin with the PD-1/CTLA-4 bispecific antibody will remodel the immune microenvironment and improve surgical outcomes.
Study Design: This is a single-center, open-label (with blinded assessment), randomized Phase II trial. Approximately 82 eligible patients will be stratified by FIGO stage (IIIC vs. IV) and randomized 1:1 to the experimental or control arm.
Neoadjuvant Phase: Patients receive 3 cycles of therapy (Q3W).
Surgical Phase: Patients with responsive or stable disease will undergo Interval Debulking Surgery (IDS). The primary endpoint is the R0 resection rate (no macroscopic residual disease).
Adjuvant Phase: Post-surgery, patients will continue treatment with the assigned regimen for additional cycles.
Translational Research: Tumor tissue, ascites, and peripheral blood will be collected at baseline, pre-surgery, and during therapy to analyze changes in immune cell subsets (e.g., via scRNA-seq, mIHC/mIF) and identify potential predictive biomarkers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive Nab-paclitaxel (260 mg/m\^2), Carboplatin (AUC 4-5), and Aitua Combination Antibody (5 mg/kg) intravenously on Day 1 of each 3-week cycle for 3 cycles as neoadjuvant therapy, followed by Interval Debulking Surgery (IDS).
Drug: Aitua Combination Antibody · Drug: Albumin-Bound Paclitaxel /nab-Paclitaxel · Drug: Carboplatin (AUC 5) · Procedure: Interval Debulking Surgery
Participants receive Nab-paclitaxel (260 mg/m\^2) and Carboplatin (AUC 4-5) intravenously on Day 1 of each 3-week cycle for 3 cycles as neoadjuvant therapy, followed by Interval Debulking Surgery (IDS).
Drug: Albumin-Bound Paclitaxel /nab-Paclitaxel · Drug: Carboplatin (AUC 5) · Procedure: Interval Debulking Surgery
Drug page: Iparomlimab/TuvonralimabStudies of Iparomlimab/TuvonralimabIparomlimab/Tuvonralimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Administered via intravenous infusion at a dose of 5 mg/kg on Day 1 of each 3-week cycle.
Also known as: PD-1/CTLA-4 Bispecific Antibody, QL1706
Drug page: Albumin-Bound PaclitaxelStudies of Albumin-Bound PaclitaxelAlbumin-Bound Paclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Administered via intravenous infusion at a dose of 260 mg/m\^2 on Day 1 of each 3-week cycle.
Administered via intravenous infusion at a dose of AUC 5 on Day 1 of each 3-week cycle.
Performed after 3 cycles of neoadjuvant therapy. The goal is to achieve R0 resection (no macroscopic residual disease).
Rate of R0 resection
Defined as the percentage of participants achieving optimal debulking surgery with no macroscopic residual disease (R0) after neoadjuvant therapy. This is assessed by the surgeon at the time of interval debulking surgery (IDS).
Time frame: At the time of surgery, up to 12 weeks
Pathological complete response (pCR) rate
Defined as the proportion of participants with no evidence of invasive cancer in the surgical specimens collected during interval debulking surgery (IDS).
Time frame: At the time of surgery, up to 12 weeks
Objective response rate (ORR)
Defined as the percentage of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, based on independent radiological review.
Time frame: From baseline up to approximately 2 years
Disease control rate (DCR)
Defined as the percentage of participants who achieve a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Time frame: From baseline up to approximately 2 years
Progression-free survival (PFS)
Defined as the time from randomization to the first documented disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death from any cause, whichever occurs first.
Time frame: From randomization up to approximately 2 years
Incidence and severity of adverse events (AEs)
Safety will be assessed by monitoring the frequency and severity of adverse events (AEs) and serious adverse events (SAEs), graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. This includes monitoring for immune-related adverse events (irAEs).
Time frame: Through 28 days after the last dose of study drug, up to approximately 2 years
Change from baseline in EORTC QLQ-C30 quality-of-life scores
Patient-reported health-related quality of life will be assessed using the 30-item European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Global health status/quality of life, functioning, and symptom scores will be calculated separately and transformed to a 0-100 scale according to the EORTC scoring manual. Higher global health status/quality of life and functioning scores indicate better outcomes, whereas higher symptom and financial difficulty scores indicate worse outcomes. Change from baseline will be assessed at each scheduled post-baseline visit.
Time frame: Baseline (before dosing on Cycle 1 Day 1), before dosing on Day 1 of Cycles 2 and 3, and within 7 days before interval debulking surgery (up to approximately 12 weeks).
Change from baseline in EORTC QLQ-OV28 domain scores
Patient-reported ovarian cancer-specific quality of life will be assessed using the 28-item European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Ovarian Cancer Module (EORTC QLQ-OV28). The questionnaire assesses abdominal/gastrointestinal symptoms, peripheral neuropathy, other chemotherapy side effects, hormonal/menopausal symptoms, body image, attitude to disease/treatment, and sexual functioning. Domain scores will be calculated separately and transformed to a 0-100 scale. Higher symptom/problem scores indicate worse outcomes; sexual functioning scores will be oriented so that higher scores indicate better functioning. Change from baseline will be assessed at each scheduled post-baseline visit.
Time frame: Baseline (before dosing on Cycle 1 Day 1), before dosing on Day 1 of Cycles 2 and 3, and within 7 days before interval debulking surgery (up to approximately 12 weeks).
Change in tumor immune microenvironment (TiME) characteristics
Exploratory analysis of immune cell subsets, such as cluster of differentiation 8 positive (CD8+) T cells, regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), in tumor tissue and peripheral blood. This uses single-cell RNA sequencing (scRNA-seq), multiplex immunohistochemistry/immunofluorescence (mIHC/mIF), and flow cytometry to evaluate the immunomodulatory effects of the treatment.
Time frame: At baseline, and at the time of surgery (up to 12 weeks)
Plan to share: No — Due to institutional privacy regulations and patient confidentiality, individual participant data (IPD) will not be shared publicly.
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for May 2027, 10 months after the start.
Of 98 non-industry phase 2 interventional studies under Fallopian Tube Neoplasms, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's planned 10 months is below that.
Counting every sponsor, half of 125 studies reached it within 56 months; a quarter within 42 and three quarters within 90.
Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Jul 2026, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iparomlimab/Tuvonralimab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences →